Inclusion Criteria:~1. Men and women age 55 to 85 years, inclusive.~2. Willing and able to provide informed
consent.~3. Must have mild cognitive impairment (MCI) or mild AD with evidence of progression (Mild-AD), as
defined by the following:~ 1. CDR-Global Score of 0.5 or 1.0, with CDR memory subscore of at least 0.5.~ 2.
MMSE score ranging from 20 to 28, inclusive.~ 3. Positive biomarker for AD, as defined by a CSF AÎ²1-42R below
the threshold and phospho-tau above the threshold for the assay utilized in the study and assessed by the
central laboratory.~4. Computed tomography (CT) or magnetic resonance imaging (MRI) findings within 2 years of
Screening that are compatible with AD and no other pathologic processes that might potentially account for the
subject's cognitive impairment.~5. If the subject is taking a single drug for AD (e.g., donepezil or other
cholinesterase inhibitors or memantine; dual therapy is excluded), he/she has been on a stable dose for at
least 2 months prior to baseline, and the dose must remain unchanged during the study unless required for
management of adverse events (AEs).~6. Adequate visual and auditory abilities to perform all aspects of the
cognitive and functional assessments.~7. Must have reliable informant or caregiver.~
